ALK-positive Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis (2024) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | GSK, Novartis, AstraZeneca, Pfizer, Roche, Merck, Ariad Pharma, Takeda

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"ALK-positive Non-Small Cell Lung Cancer Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the ALK-positive Non-Small Cell Lung Cancer Therapeutics Market.

The report provides a detailed description of the ALK-positive Non-Small Cell Lung Cancer drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the ALK-positive Non-Small Cell Lung Cancer Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

ALK-positive Non-Small Cell Lung Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing ALK-positive Non-Small Cell Lung Cancer therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ALK-positive Non-Small Cell Lung Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging ALK-positive Non-Small Cell Lung Cancer drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the ALK-positive Non-Small Cell Lung Cancer treatment market.

Learn More about the Clinical and Commercial Development Activities in the ALK-positive Non-Small Cell Lung Cancer Therapeutics Domain @
https://www.delveinsight.com/report-store/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

ALK-positive Non-Small Cell Lung Cancer Therapeutics Analysis
There are several genetic mutations identified to play a major role in the progression of this indication. Mutations in EGFR, KRAS, and ALK are mutually exclusive in patients with NSCLC, and the presence of one mutation instead of another can influence response to targeted therapy.

Chromosomal rearrangements of the ALK gene define a distinct molecular subgroup of NSCLC. ALK rearrangements lead to expression of constitutively activated ALK fusion proteins that function as potent oncogenic drivers. Since the discovery of ALK rearrangements in NSCLC, several ALK inhibitors have been developed for the treatment of patients with advanced ALK-rearranged NSCLC.

Until recently, the first-generation ALK inhibitor Crizotinib was the standard therapy for newly diagnosed ALK-positive NSCLC, however, for patients relapsing on Crizotinib, second-generation ALK inhibitors, such as Ceritinib, Alectinib, and Brigatinib, have become standard treatments, which have helped in re-prompting responses in the majority of Crizotinib-resistant patients.

There are approx. 30+ key companies developing therapies for ALK-positive Non-Small Cell Lung Cancer. The companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Betta Pharmaceuticals/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, Pfizer etc.

ALK-positive Non-Small Cell Lung Cancer Companies in the Therapeutics Market Include:
• GlaxoSmithKline
• Novartis
• AstraZeneca
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck
• Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• Ariad Pharmaceutica
• Takeda
• Chia Tai Tianqing Pharmaceutical Group
• Akeso
And Many Others

Emerging and Marketed ALK-positive Non-Small Cell Lung Cancer Therapies Covered in the Report Include:
• Ensartinib: Betta Pharmaceuticals/Xcovery
• TQ-B3139 - Chia Tai Tianqing Pharmaceutical Group
And Many More

Get an in-depth Assessment of the Emerging Therapies and ALK-positive Non-Small Cell Lung Cancer Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging ALK-positive Non-Small Cell Lung Cancer Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intramuscular
• Intratumoral
• Intravenous

Molecule Type
Products have been categorized under various Molecule types such as
• Gene therapies
• Bispecific antibodies
• Immunotherapies
• Monoclonal antibodies
• Small molecules

Request for Sample PDF to Understand More About the ALK-positive Non-Small Cell Lung Cancer Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. ALK-positive Non-Small Cell Lung Cancer Current Treatment Patterns
4. ALK-positive Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. ALK-positive Non-Small Cell Lung Cancer Late-Stage Products (Phase-III)
7. ALK-positive Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. ALK-positive Non-Small Cell Lung Cancer Discontinued Products
13. ALK-positive Non-Small Cell Lung Cancer Product Profiles
14. ALK-positive Non-Small Cell Lung Cancer Companies
15. ALK-positive Non-Small Cell Lung Cancer Drugs
16. Dormant and Discontinued Products
17. ALK-positive Non-Small Cell Lung Cancer Unmet Needs
18. ALK-positive Non-Small Cell Lung Cancer Future Perspectives
19. ALK-positive Non-Small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.